and 4/27 (14.8%) at 36 months. Multi-agent TACE with lipiodol, doxorubicin and cisplatin provides a days (range 90 to >1680 days) in 33/34 (97.1%) patients in whom progress hepatic arteriography useful anti-tumour effect, even in cirrhotic patients with large HCCs. The incidence of clinically significwas performed. Ablation of tumour neovascularity occurred in 6/6 (100%), 4/12 (33.3%) and 6/16 ant deterioration in hepatic function due to ischaemia of non-tumorous liver is acceptably low, even (37.5%) patients with HCC diameters <4 cm, 4-7 cm and >8 cm, respectively (p<0.02).
Introduction
Hepatocellular carcinoma (HCC) is, worldwide, one 1 month to 8 months.5 Since 1977, transcatheter arterial chemoembolization (TACE), which comof the commonest human malignancies.1 As this tumour mostly develops in the setting of established bines targeted chemotherapy with hepatic arterial embolization, has been widely used for the managecirrhosis, screening such patients at regular intervals has facilitated the detection of an increasing number ment of patients with inoperable HCC, with evidence that tumour ablation or reduction in tumour size can of small tumours at an asymptomatic stage, when potentially curative surgical treatments are available.
be obtained, especially in the case of tumours <4-5 cm in diameter. 4, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] However, randomized However, most patients still present with large or multifocal tumours and are unsuitable for either of controlled trials have not, to date, confirmed a significant improvement in survival.17-19 The latter, the surgical options of resection or liver transplantation.2-4 These cases carry a poor prognosis, with however, is influenced not only by any possible antitumour effect of TACE but also by the severity of the untreated medium survival ranging from less than underlying liver disease and the possibility that atic resection), in the absence of contraindications including extrahepatic metastatic disease, unsuitable treatment-related ischaemic damage to non-tumorous liver may precipitate or exacerbate liver failure. vascular anatomy (main portal vein occlusion or arterio-portal shunting), renal failure (serum creatinIndeed, deterioration in liver function was observed in over 60% of treated patients, the majority cirrhotic, ine >200 mmol/l), sepsis or impaired baseline cardiac function. Thirty-three such patients with 58 in one study.18 The incidence of treatment-related complications, including worsening hepatic function tumour foci and four additional patients with single tumours <4 cm in diameter were treated with TACE and death, may be especially high in cirrhotic patients of advanced Child's class at presentaover this period. The mean diameter of the largest HCC focus was Á4 cm in the majority of patients tion. 4, 9, 12, 20 Emulsifying the chemotherapeutic agent with iodin each of the Child-Pugh class A, B and C groups (Table 1) . HCC was diagnosed on the basis of characized oil, such as lipiodol, which not only causes temporary sinusoidal embolization but also is selectteristic features on ultrasonography, biphasic computerized tomography (CT) and hepatic arteriography ively retained in HCC following injection into the hepatic artery, prolongs the contact time between on a background of histologically-proven cirrhosis. (TACE) used in combination with two chemotherapeutic agents, epirubicin and cisplatin, found favourable TACE was performed at 6-8-weekly intervals using a standard protocol. After delineating the vascular one-and two-year survival rates of 52.9% and 33.1%, respectively, with few complications. 25 anatomy at hepatic arteriography, a freshly-prepared emulsion of lipiodol, doxorubicin (50 mg) and cisplaHowever, only 45% of patients were cirrhotic, all Child's class A, and the majority of tumours, although tin (25 mg) in a final volume of 100 ml was injected into the tumour-feeding vessel. This vessel was unresectable, were small (median diameter of largest tumour focus 3 cm).
subsequently embolized using particulate material.
Patients received prophylactic intravenous antiemetic The efficacy and safety of multi-agent, lipiodolbased TACE in cirrhotic patients with larger tumours (ondansetron) and antibiotics (ciprofloxacin and metronidazole) prior to the procedure. Intravenous and more severe impairment of hepatic function has not been assessed. These are important issues, in antibiotics were continued overnight, followed by oral dosages for a further 3 days. Patients were view of the lack of alternative treatment options of proven benefit in this group. Here we report a singledischarged on the morning following TACE on the anti-oestrogen, tamoxifen, at a dosage of 60 mg daily. centre experience with multi-agent TACE using lipiodol, doxorubicin (an agent structurally related to
The efficacy of TACE was monitored arteriographically by determining the rates of increased, stable, epirubicin) and cisplatin, predominantly in patients with large HCCs and including those with decomreduced and ablated tumour neovascularity immediately prior to each scheduled treatment session. pensated cirrhosis, with particular regard to tumour ablation rates as determined by angiography and the Extrahepatic metastatic disease was sought by abdominal and thoracic CT and bone scanning when incidence of treatment-associated deterioration in hepatic function.
indicated by symptoms, clinical signs or an increased AFP level. The Child-Pugh status was calculated prior to each session of TACE. Treatment was continued until ablation of tumour neovascularity, the taken not to proceed with further TACE were subsequently assessed by progress CT scanning and AFP poor hepatic functional reserve, bilobar or centrallylocated tumour or vascular invasion precluding hepmeasurements rather than hepatic arteriography. 1 (20.0) Patients in whom ablation of tumour neovascularity probability level of p<0.05 was set for statistical significance. was achieved were subsequently followed with serial abdominal CT scanning and AFP measurements at 3 monthly intervals (or as clinically indicated) and with confirmatory hepatic arteriography as necessary for Results assessment of further HCC development.
Serial changes in tumour neovascularity Statistical analyses
A total 148 sessions of TACE were performed, including a median 3.5 (range 1-6) sessions in Statistical analyses used Fisher's exact test and the Kruskal-Wallis rank sum test. Where a significant patients with HCC diameter <4 cm, 4.5 (2-10) sessions in patients with HCC diameter 4-7 cm and difference between three groups was demonstrated by the latter test, pairwise comparisons between 4 (1-7) sessions in patients with HCC diameter Á8 cm. Tumour neovascularity was assessed by groups were subsequently performed using the MannWhitney rank sum test (Systat for Windows). The serial hepatic arteriography in 34/37 (91.9%) patients; three patients with hepatic decompensation after the Ablation of tumour neovascularity was achieved in 16/34 (47.1%) patients, including all six patients first session of TACE did not undergo further hepatic arteriography. In 33 of these 34 (97.1%), stable, with HCC diameter <4 cm. The incidence of ablation of tumour neovascularity was significantly higher reduced or ablated tumour neovascularity (Figure 1 ) was demonstrated for a median 390 days (range 90 in this group compared to patients with tumours either 4-7 cm or Á8 cm in diameter (Table 2 ) but to >1680 days), including a median 510 days (range 260 to >930 days) in patients with HCC diameter was not significantly different in patients in whom unifocal or multifocal HCCs were treated (6/15, <4 cm, a median 330 days (range 150 to >1680 days) in patients with HCC diameter 4-7 cm and a 40.0% vs. 10/19, 52.6%; p=0.51). Significantly more sessions of TACE were required to achieve median 340 days (range 50 to >1530 days) in patients with HCC diameter Á8 cm ( p=0.36).
ablation of tumours Á8 cm in diameter compared to tumours <4 cm in diameter (Table 2) . After a median follow-up of 240 days (range 60-1120 days) following ablation of tumour neovascularity, recurrent HCC at the site of the original tumour was documented in 8/16 (50.0%) patients. HCC recurrence occurred both in patients with initial HCC diameter <4 cm as well as those with larger initial tumours. HCC recurrence did not necessarily occur earlier in patients with larger initial tumours ( Table 2) . New HCC in the contralateral lobe of liver was documented after 360 days follow-up in 1/16 (6.3%) patients whose initial tumour had been ablated. Pugh B and 11 as Child-Pugh C. The incidence of Pugh C ( p>0.1). Those hospitalized included a patient with a 4 cm HCC and pre-existing ascites (45.5%) for Child-Pugh C ( p=1.0). The incidence of deterioration in Child-Pugh status was not significwho deteriorated from Child-Pugh class B to C due to increased ascites, and developed spontaneous antly related to either the initial size of the largest HCC focus or the number of tumour foci treated bacterial peritonitis (SBP) 5 days after the first session of TACE. Another patient with an 8 cm HCC deterior- (Table 3) . No patient had progressive disease at the time of deterioration in Child-Pugh status.
ated from Child-Pugh class B to C on account of increased ascites and hepatic encephalopathy 10 Most patients returned to their employment and/or normal daily activities between treatment sessions days after the first session of TACE. The remaining two patients who required unscheduled hospitalizawithout change to their management. Unscheduled hospitalization after a session of TACE was necessary tion, each Child-Pugh class C, had HCCs <4 cm in diameter and developed increased jaundice, on 4/148 (2.7%) occasions, including 0/75 (0%) in prothrombin time, ascites and hepatic encephalopa- Discussion successful ablation by TACE may not necessarily improve long-term, tumour-free survival. Liver transThis experience has demonstrated that varying degrees of control of tumour neovascularity for a plantation may offer the best long-term outcome in this circumstance, although experience is currently median period in excess of 1 year may be achieved in over 97% of cirrhotic patients with inoperable limited. TACE was well-tolerated by the majority of HCC when treated with a multi-agent chemoembolization regimen including lipiodol, doxorubicin and patients. In keeping with other reports,34 most patients experienced some degree of right upper cisplatin. Tamoxifen was originally incorporated into the treatment protocol after reports of possible surquadrant pain, anorexia, nausea or fever in the first 24 h following the procedure. However, in only one vival benefit in patients with advanced disease,26 although its contribution to the anti-tumour effect patient did these symptoms delay discharge, which was scheduled for the morning after the procedure observed in this study is questionable in view of the lack of efficacy subsequently demonstrated in the rather than up to 1 week later as in other protocols.34 Most patients returned to their employment and/or largest controlled trial so far reported.27 Furthermore, in no reported study has tumour ablation been were able to undertake their usual daily activities between treatment sessions. The occurrence of alopeachieved with tamoxifen alone. In keeping with experiences of TACE with single chemotherapeutic cia, a recognized side-effect of doxorubicin, in two patients with advanced liver failure, suggests that agents,4,7,12,16 tumour ablation rates were significantly related to initial HCC size. Ablation of tumour systemic toxicity may ensue, especially when hepatic drug metabolism is likely to be substantially neovascularity was achieved in all patients with HCC diameter <4 cm, while, in those with larger impaired. This is in keeping with recent pharmacokinetic data suggesting that at least some release of tumours, significantly fewer tumours were ablated and only after significantly more treatment sessions. chemotherapeutic agents from the lipiodol emulsion into the systemic circulation is to be expected.35 Nonetheless, ablation of tumour neovascularity could still be achieved in at least one third of patients with Overall, less than 13% of sessions of TACE were followed by deterioration in Child-Pugh status. The HCC diameters 4-7 cm or Á8 cm. TACE was equally applicable to patients with unifocal and multifocal possibility that tumour progression may have contributed to hepatic decompensation could be excluded disease, since tumour ablation rates were comparable in these groups. in all cases. The incidence of deterioration in liver function following a session of TACE was not significFifty percent of patients in whom ablation of tumour neovascularity was achieved have shown no antly related to either the size of the largest HCC focus or the number of tumour foci treated. In evidence of tumour recurrence during follow-up periods up to 3 years. However, recurrent HCC at keeping with previous experiences,4,9,12,20 the risk of deterioration in liver function following an individual the site of the original tumour was documented in the remaining 50% of patients, all within 1 year of session of TACE was highest (20.8%) in patients categorized as Child-Pugh C. Since the majority of arteriographic evidence of tumour ablation, a finding comparable to that reported after lipiodol-based patients underwent multiple sessions of TACE, the overall incidence of deterioration in Child-Pugh TACE with a single chemotherapeutic agent.28 Although the incidence of HCC recurrence was status throughout the course of treatment was 45.5% in this group. However, no change to management highest in those patients with the largest initial tumours, tumour recurrence was also documented was necessary in the majority of patients in whom deterioration in Child-Pugh status occurred. The need in one third of patients with initial tumour diameter <4 cm and time to recurrence was not related to for unscheduled hospitalization for worsening liver time had been treated for a HCC <4 cm in diameter, S82-5. while 50% had HCCs 4-7 cm in diameter and 25% 
